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SUCCESSFUL HAMSTER-TO-RAT LIVER XENOTRANSPLANTATION UNDER FK506 
IMMUNOSUPPRESSION INDUCES UNRESPONSIVENESS TO HAMSTER HEART AND SKIN1 
In addition to its well-known resistance to antibody (1) and 
cell-mediated (2) rejection, the liver allograft can confer these 
advantages to other tissues and organs transplanted concomi-
tantly or subsequently from the donor or donor strain (3, 4). 
We report here an example of this same hepatic tolerogenicity 
after hamster livers were transplanted to rats under FK506, 
ameliorating thereafter the otherwise intractable rejection of 
hamster heart and skin xenografts. 
Before performing these "shielding" experiments, we first 
confirmed and extended our earlier observations (5, 6) of the 
liver xenograft's privileged state relative to other organs. Full-
thickness hamster skin grafts were debrided of fatty tissue, 
sutured onto the chest of Lewis (LEW, RTll) rat recipients, 
inspected daily after the 6th day, and scored as rejected on the 
first day of total epithelial necrosis. Hamster heart grafts were 
placed in the abdominal cavity by anastomosing the graft aorta 
and pulmonary artery end-to-side to the recipient's abdominal 
aorta and inferior vena cava, respectively (6); rejection was 
defined by cessation of the heartbeat on abdominal palpation. 
Liver grafts replaced the recipient's own organ and were revas-
cularized with portal venous blood only (6); graft rejection was 
defined as the time of the animal's death. 
In these preliminary experiments, hamster hearts in un-
treated rat recipients were destroyed by xenospecific antibodies 
in 3±0.0 (SD) days, whereas livers survived this initial insult 
and were rejected by combined humoral and cellular rejection 
at 7.0±0.5 days, one day later than full-thickness grafts of skin 
(6.0±0.7) (Fig. lA). When the rats were treated daily with the 
T cell-directed immunosuppressant FK506, heart xenograft 
survival was not prolonged by FK506 and the effect on skin 
grafts was minimal. In contrast, liver xenograft survival time 
was increased 10-fold, with 30% of the liver recipients living 
>100 days (Fig. lB). 
As reported elsewhere (6), microvascular platelet/fibrin 
thrombi, hemorrhage, and necrosis caused by antibody rejection 
in the heart and liver xenografts were associated with vascular 
binding of immunoglobulins (lgM > IgG) that contempora-
neously rose dramatically in serial plasma samples. In the 
untreated liver recipients, splenomegaly was invariable by the 
time of death at 6-7 days. However, under FK506, splenomegaly 
was not prominent and heterophile antibody titers that rose 
initially as in untreated animals declined to baseline levels after 
reaching a peak on the 5th or 6th day. In selected liver xenograft 
recipients under FK506, sequential biopsies during the first 30 
days showed self-resolving humoral, then humoral-cellular, and 
finally predominantly cellular rejection. 
The first invading immunocytes in treated or untreated re-
cipients were predominantly OX8+ /OX19+ (cytotoxic T), and 
NKR-Pl + (natural killer) cells. In contrast to the typical local-
ization of mononuclear infiltrates to the portal triads of allo-
grafts, these cells were distributed throughout the hepatic si-
nusoids (6). The cells disappeared in the surviving xenografts 
under FK506, and in later samples it was shown with immu-
nophenotypic detection techniques that chronically surviving 
grafts always had extensive replacement of donor Kupffer and 
dendritic cells by those of the recipient (7). The cell repopula-
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tion and graft chimera formation were similar to that which 
occurs in accepted liver allografts (8, 9). The other histopa-
thology of long-surviving xenografts ranged from normal to 
various stages of rejection. The most common cause of late 
graft failure was intra- or extrahepatic biliary obstruction. 
The surviving liver recipients from the foregoing preliminary 
experiments were used for shielding experiments. LEW rats 
bearing hamster livers for 40-50 days under daily FK506 had 
their immunosuppression stopped for 2 weeks on the day of 
skin or cardiac transplantation from third-party (outbred) 
hamsters or from C3H mice. These animals (Table 1, group 3) 
freely accepted skin and cardiac grafts from third-party ham-
sters. At the same time, they retained the same ability to reject 
C3H mouse skin and heart xenografts as that possessed by 
control rats that had had drug pretreatment only (Table 1, 
group 2). These LEW (RT1l) recipients also rejected skin 
allografts from ACI (RTl") donors in 11-13 days (n=5). To 
rule out the possibility that the results were due in part to 
residual immunosuppression from the prior chronic FK506 
therapy, control LEW rats without liver transplantation were 
pretreated for 30 days with 1 mg/kg/day FK506 before test 
heart or skin xenotransplantation, after which no treatment 
was given. When transplanted alone, survival of the hamster 
skin was prolonged an average of 3.0 days by the 30-day 
pretreatment (P<O.Ol) but survival of the hamster heart xen-
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FIGURE 1. Hamster-to-rat xenotransplantation (A) Graft survival 
in untreated controls; skin grafts (open square [n",5j), heart grafts 
(open circles [n"'6j); and liver grafts (closed circles [n=8]). (B) An 
intramuscular injection of 1 mg/kg/day FK506 was given daily for the 
first 30 posttransplant days and half this daily dose thereafter until 
day 100. Symbols as in (A): skin grafts (n=5), heart grafts (n=6), and 
liver grafts (n=10). 
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TABLE 1. Results of hamster and mouse skin or heart xenotransplantation to LEW rats 40-50 days after successful xenografting of hamster 
liver (OLT) 
Survival days 
Recipient treatment Skin graft Heart graft 
Hamster C3H mice Hamster C3H mice 
None 
FK506 (1 mg/kg/day x30) 
Prior OL T and daily FK506 a 
5,6,6,6,7 
8,9,9,9,10 
22 b,33,62 b,69 
73,78,78,89 
6,6,7,7,8 
9,10,10,10,10 
9,10,11,12 
3,3,3,3,3,3 
3,3,3,4 
54,60b,73,120 
2,2,3,3 
2,2,2,3 
2,3,3,3 
a The protocol of FK506 treatment is described in the legend to Figure 1. When skin or heart grafts were grafted between 40 and 50 days after 
liver transplantation, immunosuppression was stopped for 2 weeks and then restarted at 0.5 mg/kg every other day up to day 100. 
b Recipients died of biliary obstruction with grafts intact. 
TABLE 2. Evidence that LEW rats accept equally liver donor and 
3RD-party hamster skin engrafted on the day of liver 
xenotransplantation 
OLT FK506" Skin donor Skin graft survival 
No No Hamster 5,6,6,6,7 
No Yes Hamster 8,8,9,9,9, 
Yesb Yes Hamster liver donor 15',40',54',60',> 130 
Yes b Yes Third party hamster 15',40',54 ',60',> 130 
• Immunosuppression was started on the day of transplantation, as 
described in the legend to Figure 1. 
b Skin and liver graft survival were synonymous. 
, Recipients died of biliary obstruction with grafts intact. 
ografts was the same as in the untreated controls. Mouse skin 
(P<O.OI), but not mouse hearts, also had slight prolongation 
of survival after recipient pretreatment (Table 1, group 2). 
The lack of strict donor specificity of the liver-induced 
tolerogenicity to the hamster organs was studied further in 5 
LEW rats who were given 2 full-thickness skin grafts on the 
day of liver xenotransplantation under FK506-one from the 
liver donor, and the other from a third-party hamster. All 10 
skin grafts were accepted for as long as the liver recipients 
survived, in contrast to invariable skin graft rejection in non-
liver recipients given the same immunosuppression (Table 2). 
In hamster-to-hamster allograft controls, skin grafts in non-
immunosuppressed animals were rejected in 13.1±4.2 (SD) days 
(n=6, range 11-16 days). Although the relatively long skin 
survival suggested that there was a good average histocompat-
ibility within the Syrian hamsters, the experiments eliminated 
the possibility that the hamster colony was inbred to a synge-
neic state. 
These experiments have shown that a multifaceted immu-
nologic privilege enjoyed by the liver in the moderately difficult 
hamster-to-rat xenograft model is qualitatively similar to that 
in hepatic allotransplantation models. The hamster-to-rat spe-
cies combination can be categorized as "semidiscordant" be-
cause of the xenospecific hyperacute (antibody-mediated) re-
jection of the heart, but not the liver, that occurs after 3 days. 
Numerous explanations have been advanced to explain the 
liver's relative ability to withstand an antibody insult (10) 
including the protection to its microvasculature provided by a 
double blood supply (not relevant in our experiments in which 
the livers were not arterialized); its large microvascular surface 
available for antibody absorption; its secretion of new donor-
specific soluble class I antigens (11) or IgG types (8) that 
theoretically could neutralize preformed antigraft antibodies; 
and the special qualities of its sinusoidal bed. This last possi-
bility has had a special appeal because of the discovery by 
Porter in 1969 that the Kupffer cells and macrophages lining 
the sinusoids are quickly replaced in all successful hepatic grafts 
with recipient cells although the hepatocytes permanently re-
tain their donor specificity (8). 
It is now suspected that this cell repopulation, which also 
includes lymphoid and dendritic cells, is a generic phenomenon 
critical to the "acceptance" of any organ allograft and respon-
sible as well for hepatic tolerogenicity (9). The extent to which 
the seeding of donor cells and consequent systemic microchi-
merism occur depends on the immunologic substrate (especially 
the amount of bone marrow-derived dendritic cells) available 
in the donor organ for cell peripheralization. The liver is the 
most richly endowed of the solid organs with these cells. 
Achievement of the cell repopulation requires potent immuno-
suppression with agents like FK506 during the cell transition. 
In xenotransplant models, it also depends on the avoidance of 
antibody rejection, which is more easily accomplished with the 
liver than other organs. The reason why the hepatic tolerogen-
icity that ensues is species- but not individual-specific may be 
the genetic similarity of hamsters even when they are outbred. 
This demonstration of hepatic tolerogenicity in a xenograft 
model could have clinical implications. 
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